CureVac Enters into an Exclusive Sponsored Research Agreement for Discovery Research in mRNA-based Eye Therapy Candidates with the Schepens Eye Research Institute, Harvard Medical School and the Massachusetts Eye and Ear Infirmary

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it has entered into a sponsored research agreement (“SRA”) with Schepens Eye Research Institute of Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School, for discovery research in mRNA-based eye therapy candidates.

The exclusive SRA covers the development of an undisclosed number of novel mRNA-based candidates for undisclosed eye indications. Under terms of the SRA, CureVac will provide all funding for the discovery research. The Schepens Eye team will carry out discovery research on targets related to eye diseases and present therapeutic candidates to CureVac for preclinical and subsequent clinical development. CureVac retains the option to acquire any rights regarding the candidates.

“We are honored to partner with the Schepens team, which is performing cutting edge discovery research in the ocular field,” said Dan Menichella, CEO of CureVac. “CureVac has developed a next generation mRNA delivery vehicle, the CureVac Carrier Molecule™, to reach targets in the eye and other organs and is well suited for repeated dosing administration.”